Proceedings from the 2nd European Clinical Consensus Conference for device-based therapies for hypertension: state of the art and considerations for the future.

The interest in RDN for hypertension has fluctuated recently, with a flurry of initial enthusiasm followed by sudden loss of interest by researchers and device manufacturers, with an almost as sudden resurgence in clinical trials activity and device innovation more recently. There is widespread consensus that this therapeutic strategy can be effective, at least for some of the technologies available. Major uncertainties remain as to the clinical role of RDN, and whether any of the emerging technologies such as AV-anastomosis formation, carotid body ablation, carotid bulb expansion, or baroreflex stimulation will have a future as effective treatment options in patients with hypertension. In our first consensus report in 2015, the European Expert Group pointed to the major unmet need of standardization of measurements, trial design and procedural performance.6 With the large number of different technologies currently in the pipeline, this need has even increased. Only through high-quality, collaborative research and openness to new methods for recruitment, patient selection, and assessment of outcomes will it be possible to establish incontrovertibly whether device therapies for hypertension are effective and what are preferred patient populations. Once the proof of concept is established, further studies with a design relevant to clinical reality will be needed to establish the place of new devices in the treatment armoury. The clinical and research community has a large responsibility to prove or disprove the value of new therapies, in order to ensure that antihypertensive devices provide future patients with the greatest benefit and the smallest risk. copy; The Author 2017

LASER-RAMAN STUDY OF THE STRUCTURE OF SILVER DOPED As40S60 GLASS

The Raman spectra of Ag doped a-As2S3 glass with compositions along the pseudo-binary line As2S3-Ag2S is presented. Small amounts of Ag have little effect on the structure of a-As2S3 whereas glasses containing larger amounts (> 21 atm %) contain structural units found in corresponding crystalline forms

Development of a sensor system for the early detection of soft rot in stored potato tubers

A number of sensor types were fabricated and tested for their electrical resistance changes to compounds known to be evolved by potato tubers with soft rot caused by the bacterium Erwinia carotovora. On the basis of these tests, three sensors were selected for incorporation into a prototype device. The device was portable and could be used without computer control after threshold values and sensor settling criteria had been downloaded. The prototype was assessed for its discriminating power under simulated storage conditions. The device was capable of detecting one tuber with soft rot in 100 kg of sound tubers in a simulated storage crate. The device was also able to detect a tuber inoculated with E. carotovora, but without visible signs of soft rot, within 10 kg of sound tubers. The same system was able to follow the progression of the disease in a tuber stored amongst 10 kg of sound tubers when operated at 4 °C and 85% relative humidity (conditions typical of a refrigerated storage facility)

Gas chromatography-mass spectrometry analyses of volatile organic compounds from potato tubers inoculated with Phytophthora infestans or Fusarium coeruleum

Volatile organic compounds (VOCs) collected from potato tubers inoculated with Phytophthora infestans (late blight), Fusarium coeruleum (dry rot) or sterilized distilled water (as a control) were analysed using gas chromatography-mass spectrometry (GC-MS) and gas chromatography-flame ionization detection (GC-FID). A total of 52 volatiles were identified by GC-MS in the headspaces above P. infestans- and F. coeruleum-inoculated tubers after incubation for 42 days in the dark at 10°C. Of these VOCs, the six most abundant were common to both pathogens. These were benzothiazole (highest abundance), 2-ethyl-1-hexanol (second highest abundance), and at approximately equal third abundance, hexanal, 2-methylpropanoic acid-2,2-dimethyl-1-(2-hydroxy-1-methylethyl)-propyl ester, 2-methylpropanoic acid-3-hydroxy-2,4,4-trimethyl-pentyl ester and phenol. In addition, styrene also occurred at approximately equal third abundance in the headspace of F. coeruleum-inoculated tubers, but at lower abundance in the headspace of P. infestans-inoculated tubers. Some VOCs were specific to each pathogen. Butanal, 3-methylbutanal, undecane and verbenone were found at low levels only in the headspace of tubers inoculated with P. infestans, while 2-pentylfuran and copaene were found only in the headspace of tubers inoculated with F. coeruleum. Additionally GC-FID analysis identified ethanol and 2-propanol in the liquid exudate from both P. infestans- and F. coeruleum-inoculated tubers after incubation for 35 days, and in the headspace after incubation for 42 days. These data provide key information for developing a sensor-based early warning system for the detection of postharvest diseases in stored potato tubers

Proceedings from the 2nd European clinical consensus conference for device-based therapies for hypertension: State of the art and considerations for the future

The interest in RDN for hypertension has fluctuated recently, with a flurry of initial enthusiasm followed by sudden loss of interest by researchers and device manufacturers, with an almost as sudden resurgence in clinical trials activity and device innovation more recently. There is widespread consensus that this therapeutic strategy can be effective, at least for some of the technologies available. Major uncertainties remain as to the clinical role of RDN, and whether any of the emerging technologies such as AV-anastomosis formation, carotid body ablation, carotid bulb expansion, or baroreflex stimulation will have a future as effective treatment options in patients with hypertension. In our first consensus report in 2015, the European Expert Group pointed to the major unmet need of standardization of measurements, trial design and procedural performance.6 With the large number of different technologies currently in the pipeline, this need has even increased. Only through high-quality, collaborative research and openness to new methods for recruitment, patient selection, and assessment of outcomes will it be possible to establish incontrovertibly whether device therapies for hypertension are effective and what are preferred patient populations. Once the proof of concept is established, further studies with a design relevant to clinical reality will be needed to establish the place of new devices in the treatment armoury. The clinical and research community has a large responsibility to prove or disprove the value of new therapies, in order to ensure that antihypertensive devices provide future patients with the greatest benefit and the smallest risk. copy; The Author 2017. Published by Oxford University Press on behalf of the European Society of Cardiology